Denosumab (60mg) Discount Agreement
Original notice title
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 19 - Denosumab (Wirkstärke 60mg)
Opportunity Score
Why this score?
Opportunity
45 / 100
Complexity
40 / 100
Risk factors
Non-compliance with eligibility criteria (e.g., authorization status) could lead to contract invalidation. Self-declara...
No estimated value or volume provided; actual revenue from this agreement is uncertain. Low prescription volumes could...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Nov 2027
- Supply of Denosumab (strength 60mg) pharmaceutical products
- Conclusion of discount agreements with TK and participating health insurances
Show full summary
Open House discount agreement (Rabattvertrag) for Denosumab (strength 60mg) with the Techniker Krankenkasse (TK) and participating health insurances (HEK, hkk). The procedure is a non-competitive Open House with uniform conditions, no exclusivity, and maximum 17-month duration (1 July 2026 to 30 November 2027). All qualified pharmaceutical entrepreneurs can join at any time. No estimated value is provided.
Risks
Non-compliance with eligibility criteria (e.g., authorization status) could lead to contract invalidation. Self-declara...
No estimated value or volume provided; actual revenue from this agreement is uncertain. Low prescription volumes could...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per § 4 Abs. 18 AMG with valid authorization
- Must have a registered seat in Germany, EU, or EEA
Administrative
- Must provide self-declaration regarding authorization and reliability
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Denosumab (60mg) Discount Agreement
Open House agreement for Denosumab 60mg discount contracts under § 130a Abs. 8 SGB V. Supply of pharmaceutical product with no exclusivity. Maximum 17 months from 1 July 2026 to 30 November 2027.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Denosumab (Wirkstärke 60mg) zu schließen.
Value note
Show original TED data
Original lot title
Open House Biologika Rabattverträge 2026 - 19 - Denosumab (Wirkstärke 60mg)
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Denosumab (Wirkstärke 60mg) zu schließen.
Procurement Details
- Publication date
- 25 May 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 354637-2026
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
45 / 100
Complexity
40 / 100
Risk factors
Non-compliance with eligibility criteria (e.g., authorization status) could lead to contract invalidation. Self-declara...
No estimated value or volume provided; actual revenue from this agreement is uncertain. Low prescription volumes could...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications